Biotech CEO podcast with Huahui CSO Li Wenhui

Huahui Health CSO Li Wenhui sits down with Scrip in the office to discuss many of the key issues such as, how he views antivirals development post-COVID? how the company’s hepatitis drugs differentiated from others? Given the current antivirals from Gilead among others, why Li believed that the antiviral development remains vital?